Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised shares of Anixa Biosciences to a “strong-buy” rating in a research report on Wednesday, August 7th.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $3.20 on Tuesday. The firm has a market cap of $102.98 million, a PE ratio of -8.20 and a beta of 0.84. The firm’s 50 day simple moving average is $3.25 and its 200-day simple moving average is $2.99. Anixa Biosciences has a one year low of $2.14 and a one year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Equities research analysts predict that Anixa Biosciences will post -0.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors have recently bought and sold shares of the business. Westside Investment Management Inc. increased its holdings in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after buying an additional 21,100 shares during the period. Virtu Financial LLC purchased a new position in Anixa Biosciences during the third quarter valued at approximately $34,000. Tyler Stone Wealth Management increased its holdings in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares during the period. International Assets Investment Management LLC increased its holdings in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after buying an additional 23,800 shares during the period. Finally, Concorde Asset Management LLC purchased a new position in Anixa Biosciences during the second quarter valued at approximately $31,000. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.